120 related articles for article (PubMed ID: 15369136)
21. Interferon--a major regulator of natural killer cell-mediated cytotoxicity.
Reiter Z
J Interferon Res; 1993 Aug; 13(4):247-57. PubMed ID: 7693829
[TBL] [Abstract][Full Text] [Related]
22. Differential cytokine regulation of natural killer cell-mediated necrotic and apoptotic cytotoxicity.
Gardiner CM; Reen DJ
Immunology; 1998 Apr; 93(4):511-7. PubMed ID: 9659223
[TBL] [Abstract][Full Text] [Related]
23. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
[TBL] [Abstract][Full Text] [Related]
24. Can the dual-functional capability of CIK cells be used to improve antitumor effects?
Wang X; Yu W; Li H; Yu J; Zhang X; Ren X; Cao S
Cell Immunol; 2014 Jan; 287(1):18-22. PubMed ID: 24355711
[TBL] [Abstract][Full Text] [Related]
25. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines.
Wang MH; Flad HD; Böhle A; Chen YQ; Ulmer AJ
Immunol Lett; 1991 Mar; 27(3):191-7. PubMed ID: 2060970
[TBL] [Abstract][Full Text] [Related]
26. The role of natural killer cells and lymphokine activated killer cells in the pathogenesis of hepatic injury in hepatitis A [corrected].
Baba M; Fukai K; Hasegawa H; Nakayabu M; Suzuki S
J Clin Lab Immunol; 1992; 38(1):1-14. PubMed ID: 1343344
[TBL] [Abstract][Full Text] [Related]
27. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
28. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2.
Uharek L; Zeis M; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N; Müller-Ruchholtz W
Leukemia; 1996 Nov; 10(11):1758-64. PubMed ID: 8892679
[TBL] [Abstract][Full Text] [Related]
29. Measurement of cytotoxic activity of NK/LAK cells.
Whiteside TL
Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.18. PubMed ID: 18432832
[TBL] [Abstract][Full Text] [Related]
30. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
[TBL] [Abstract][Full Text] [Related]
31. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells.
Karlhofer FM; Ribaudo RK; Yokoyama WM
Nature; 1992 Jul; 358(6381):66-70. PubMed ID: 1614533
[TBL] [Abstract][Full Text] [Related]
32. Natural cytotoxicity of human blood monocytes and natural killer cells and their cytotoxic factors: discriminating effects of actinomycin D.
Uchida A; Klein E
Int J Cancer; 1985 May; 35(5):691-9. PubMed ID: 3997288
[TBL] [Abstract][Full Text] [Related]
33. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215
[TBL] [Abstract][Full Text] [Related]
34. Suramin inhibits tumor cell cytotoxicity mediated through natural killer cells, lymphokine-activated killer cells, monocytes, and tumor necrosis factor.
LaPushin R; Totpal K; Higuchi M; Aggarwal BB
J Clin Immunol; 1994 Jan; 14(1):39-49. PubMed ID: 8132736
[TBL] [Abstract][Full Text] [Related]
35. The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis.
Chiang EY; Henson M; Stroynowski I
J Immunol; 2002 Mar; 168(5):2200-11. PubMed ID: 11859106
[TBL] [Abstract][Full Text] [Related]
36. Cell death protection by 3-aminobenzamide and other poly(ADP-ribose)polymerase inhibitors: different effects on human natural killer and lymphokine activated killer cell activities.
Monti D; Cossarizza A; Salvioli S; Franceschi C; Rainaldi G; Straface E; Rivabene R; Malorni W
Biochem Biophys Res Commun; 1994 Mar; 199(2):525-30. PubMed ID: 8135793
[TBL] [Abstract][Full Text] [Related]
37. An improved flow cytometry-based natural killer cytotoxicity assay involving calcein AM staining of effector cells.
Jang YY; Cho D; Kim SK; Shin DJ; Park MH; Lee JJ; Shin MG; Shin JH; Suh SP; Ryang DW
Ann Clin Lab Sci; 2012; 42(1):42-9. PubMed ID: 22371909
[TBL] [Abstract][Full Text] [Related]
38. Measurement of NK activity by the microcytotoxicity assay (MCA): a new application for an old assay.
Wahlberg BJ; Burholt DR; Kornblith P; Richards TJ; Bruffsky A; Herberman RB; Vujanovic NL
J Immunol Methods; 2001 Jul; 253(1-2):69-81. PubMed ID: 11384670
[TBL] [Abstract][Full Text] [Related]
39. Reinforced cytotoxicity of lymphokine-activated killer cells toward glioma cells by transfection with the tumor necrosis factor-alpha gene.
Tashiro T; Yoshida J; Mizuno M; Sugita K
J Neurosurg; 1993 Feb; 78(2):252-6. PubMed ID: 8421207
[TBL] [Abstract][Full Text] [Related]
40. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
